Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $30 to $34.
Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $30 to $34.